Welcome to the Working Group on New TB Drugs Blog
Dual Infections Of TB And AIDS Make Each Harder To Treat
Tuberculosis infects nearly ten million people each year and kills nearly two million. It is primarily a lung disease that spreads easily among people with weakened immune systems. Sub-Saharan Africa is still the epicenter of the HIV/AIDS disaster, but it is also becoming the epicenter of tuberculosis.
Interview with Gyanu Lamicchane
Dr. Gyanu Lamichhane is Assistant Professor, Division of Infectious Diseases at the Johns Hopkins University Center for Tuberculosis Research Labs. This interview was conducted at JHU on November 13, 2009.
MicuRx Pharmaceuticals and Cumencor Pharmaceuticals Partner with Pfizer to Discover and Develop Antibiotics for Drug-Resistant Tuberculosis in China
MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer (NYSE: PFE) to discover novel therapeutic agents to treat multi-drug resistant tuberculosis (MDR-TB). Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx’s proprietary technology platform to discover and develop novel antibiotics for MDR-TB.
North America’s Sole Manufacturer of MDR-TB Drugs Closing Its Doors
An Indiana drug maker that’s North America’s sole manufacturer of a multidrug-resistant tuberculosis drug is closing its doors after five years. The Purdue Research Foundation says the Chao Center for Industrial Pharmacy and Contract Manufacturing was unable to become self-sustaining in part because of the recession.
WHO Releases New MDR/XDR Report
In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.
For example, 28% of all people newly diagnosed with TB in one region of north western Russia had the multidrug-resistant form of the disease (MDR-TB) in 2008. This is the highest level ever reported to WHO. Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in 2007.
MDR-TB patients face discrimination, long road to recovery in Peru
Video: Patients who develop multi-drug resistant tuberculosis face an arduous course of medical treatment. What’s worse, many say, is being ostracized by friends and neighbors who fear the dreaded disease.
Dr. Lee Reichman responds to TB and Haiti crisis
Last week, a story in the NY Times explored the emerging threat of drug-resistant TB spreading in the aftermath of the tragic earthquake in Haiti.
On Sunday, Feb 14, the NY Times published in a letter to editor from Dr. Lee Reichman, MD, MPH (Professor and Executive Director, UMDNJ-New Jersey Medical School Global Tuberculosis Institute) in [...]
-
Toppix TB News- Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. 8 Sep 2010
- Global Fund needs U.S. support 8 Sep 2010
- New park memorializes ORC 7 Sep 2010
- Experimental TB test called fast, accurate 7 Sep 2010
- People with diabetes up to 2-3 times higher risk of TB 7 Sep 2010
